Search Results

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics (ACMG), published a new study validating RiskScore®, Myriad’s breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced a collaboration with GSK aimed at improving access to homologous recombination deficiency diagnostic testing for high-grade serous ovarian cancer patients.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced that JCO Precision Oncology has published a study showing a clinical cell-cycle risk score can accurately predict the benefit of adding androgen deprivation therapy to radiation therapy in men with localized prostate cancer.

Renovaro Inc. and the Amsterdam UMC Cancer Center announced an intended partnership and therefore signed an MoU to establish a joint company based in the Netherlands aimed at pioneering the next generation of personalized cancer immunotherapy.

3X4 Genetics, leader in the field of genetics-based health, announced a partnership with The Metabolic Terrain Institute of Health to serve as the innovative nonprofit’s genetics provider.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies at the 2024 ASCO Annual Meeting.